Your browser doesn't support javascript.
loading
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia.
Stein, Eytan M; DeAngelo, Daniel J; Chromik, Jörg; Chatterjee, Manik; Bauer, Sebastian; Lin, Chia-Chi; Suarez, Cristina; de Vos, Filip; Steeghs, Neeltje; Cassier, Philippe A; Tai, David; Kiladjian, Jean-Jacques; Yamamoto, Noboru; Mous, Rogier; Esteve, Jordi; Minami, Hironobu; Ferretti, Stephane; Guerreiro, Nelson; Meille, Christophe; Radhakrishnan, Rajkumar; Pereira, Bernard; Mariconti, Luisa; Halilovic, Ensar; Fabre, Claire; Carpio, Cecilia.
Afiliación
  • Stein EM; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • DeAngelo DJ; Division of Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Chromik J; Department of Medical Oncology, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Chatterjee M; University Hospital of Würzburg, Comprehensive Cancer Center Mainfranken, Translational Oncology, Würzburg, Germany.
  • Bauer S; Department of Medical Oncology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Lin CC; German Consortium of Translational Cancer Research (DKTK), Essen, Germany.
  • Suarez C; National Taiwan University Hospital, Taipei, Taiwan.
  • de Vos F; Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Steeghs N; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Cassier PA; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Tai D; Léon Bérard Center, Lyon, France.
  • Kiladjian JJ; National Cancer Center Singapore, Singapore.
  • Yamamoto N; Université de Paris, Hôpital Saint-Louis, Paris, France.
  • Mous R; National Cancer Center Hospital, Tokyo, Japan.
  • Esteve J; Department of Hematology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Minami H; Hospital Clinic, IDIBAPS, Barcelona, Spain.
  • Ferretti S; Kobe University Graduate School of Medicine and Hospital, Japan.
  • Guerreiro N; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Meille C; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Radhakrishnan R; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Pereira B; Novartis Healthcare Private Limited, Hyderabad, India.
  • Mariconti L; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Halilovic E; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Fabre C; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Carpio C; Novartis Institutes for BioMedical Research, Basel, Switzerland.
Clin Cancer Res ; 28(5): 870-881, 2022 Mar 01.
Article en En | MEDLINE | ID: mdl-34862243
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Neoplasias Hematológicas / Neoplasias Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Neoplasias Hematológicas / Neoplasias Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos